Huntington National Bank’s Aurinia Pharmaceuticals AUPH Stock Holding History

Huntington National Bank’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30	Hold	2	–	–	﹤0.01%	3223
2025 Q4	$32	Hold	2	–	–	﹤0.01%	3109
2025 Q3	$22	Hold	2	–	–	﹤0.01%	3384
2025 Q2	$17	Hold	2	–	–	﹤0.01%	3506
2025 Q1	$16	Hold	2	–	–	﹤0.01%	3564
2024 Q4	$18	Hold	2	–	–	﹤0.01%	3524
2024 Q3	$15	Hold	2	–	–	﹤0.01%	3590
2024 Q2	$11	Hold	2	–	–	﹤0.01%	3645
2024 Q1	$10	Hold	2	–	–	﹤0.01%	3548
2023 Q4	$18	Hold	2	–	–	﹤0.01%	3237
2023 Q3	$16	Hold	2	–	–	﹤0.01%	3259
2023 Q2	$19	Sell	2 -631	-100%	-$6.55K	﹤0.01%	3162
2023 Q1	$6.94K	Sell	633 -498	-44%	-$4.39K	﹤0.01%	1637
2022 Q4	$4.89K	Buy	1,131 +395	+54%	+$2.29K	﹤0.01%	1648
2022 Q3	$6K	Hold	736	–	–	﹤0.01%	1657
2022 Q2	$7K	Sell	736 -170	-19%	-$1.9K	﹤0.01%	1649
2022 Q1	$11K	Buy	906 +122	+16%	+$1.89K	﹤0.01%	1539
2021 Q4	$18K	Buy	784 +1	+0.1%	+$24	﹤0.01%	1401
2021 Q3	$17K	Sell	783 -674	-46%	-$10.7K	﹤0.01%	1298
2021 Q2	$19K	Sell	1,457 -77	-5%	-$981	﹤0.01%	1262
2021 Q1	$20K	Buy	+1,534	New	+$22.3K	﹤0.01%	1133

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Huntington National Bank's AUPH Position: Q1 2026 in Review

Huntington National Bank held its Aurinia Pharmaceuticals (AUPH) position steady in Q1 2026 at 2 shares worth $30. The position accounts for ﹤0.01% of the portfolio, ranked #3223.

Huntington National Bank first reported a position in AUPH in Q1 2021 and has held it in 21 quarters since. The position peaked at $20K in Q1 2021. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

Huntington National Bank held 2 shares of Aurinia Pharmaceuticals worth $30 as of Q1 2026.
Huntington National Bank left its Aurinia Pharmaceuticals share count unchanged in Q1 2026.
Aurinia Pharmaceuticals made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #3223 holding.
Huntington National Bank first reported a position in Aurinia Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
Huntington National Bank's Aurinia Pharmaceuticals position peaked at $20K in Q1 2021.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.